169 related articles for article (PubMed ID: 32404505)
1. PET ligands [
Lu S; Haskali MB; Ruley KM; Dreyfus NJ; DuBois SL; Paul S; Liow JS; Morse CL; Kowalski A; Gladding RL; Gilmore J; Mogg AJ; Morin SM; Lindsay-Scott PJ; Ruble JC; Kant NA; Shcherbinin S; Barth VN; Johnson MP; Cuadrado M; Jambrina E; Mannes AJ; Nuthall HN; Zoghbi SS; Jesudason CD; Innis RB; Pike VW
Sci Transl Med; 2020 May; 12(543):. PubMed ID: 32404505
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a PET Radioligand to Image
Paul S; Haskali MB; Liow JS; Zoghbi SS; Barth VN; Kolodrubetz MC; Bond MR; Morse CL; Gladding RL; Frankland MP; Kant N; Slieker L; Shcherbinin S; Nuthall HN; Zanotti-Fregonara P; Hanover JA; Jesudason C; Pike VW; Innis RB
J Nucl Med; 2019 Jan; 60(1):129-134. PubMed ID: 30213846
[TBL] [Abstract][Full Text] [Related]
3. MK-8719, a Novel and Selective
Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
[TBL] [Abstract][Full Text] [Related]
4. PET quantification of brain O-GlcNAcase with [
Lee JH; Liow JS; Paul S; Morse CL; Haskali MB; Manly L; Shcherbinin S; Ruble JC; Kant N; Collins EC; Nuthall HN; Zanotti-Fregonara P; Zoghbi SS; Pike VW; Innis RB
EJNMMI Res; 2020 Mar; 10(1):20. PubMed ID: 32172476
[TBL] [Abstract][Full Text] [Related]
5. Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
Cook BE; Nag S; Arakawa R; Lin EY; Stratman N; Guckian K; Hering H; Lulla M; Choi J; Salinas C; Genung NE; Morén AF; Bolin M; Boscutti G; Plisson C; Martarello L; Halldin C; Kaliszczak MA
J Nucl Med; 2023 Oct; 64(10):1588-1593. PubMed ID: 37934021
[No Abstract] [Full Text] [Related]
6. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
8. Region- and voxel-based quantification in human brain of [
Lee JH; Veronese M; Liow JS; Morse CL; Montero Santamaria JA; Haskali MB; Zoghbi SS; Pike VW; Innis RB; Zanotti-Fregonara P
EJNMMI Res; 2021 Apr; 11(1):35. PubMed ID: 33796956
[TBL] [Abstract][Full Text] [Related]
9. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM
J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187
[TBL] [Abstract][Full Text] [Related]
10. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
[No Abstract] [Full Text] [Related]
11. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
Li X; Han J; Bujaranipalli S; He J; Kim EY; Kim H; Im JH; Cho WJ
Eur J Med Chem; 2022 Aug; 238():114444. PubMed ID: 35588599
[TBL] [Abstract][Full Text] [Related]
12. Yeast cells as an assay system for in vivo O-GlcNAc modification.
Nakanishi H; Li F; Han B; Arai S; Gao XD
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1159-1167. PubMed ID: 28263870
[TBL] [Abstract][Full Text] [Related]
13. Hijacking of the O-GlcNAcZYME complex by the HTLV-1 Tax oncoprotein facilitates viral transcription.
Groussaud D; Khair M; Tollenaere AI; Waast L; Kuo MS; Mangeney M; Martella C; Fardini Y; Coste S; Souidi M; Benit L; Pique C; Issad T
PLoS Pathog; 2017 Jul; 13(7):e1006518. PubMed ID: 28742148
[TBL] [Abstract][Full Text] [Related]
14. Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
Kiss M; Szabó E; Bocska B; Sinh LT; Fernandes CP; Timári I; Hayes JM; Somsák L; Barna T
Eur J Med Chem; 2021 Nov; 223():113649. PubMed ID: 34186233
[TBL] [Abstract][Full Text] [Related]
15. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
[TBL] [Abstract][Full Text] [Related]
16. Development of a Novel [
Nag S; Bolin M; Datta P; Arakawa R; Forsberg Morén A; Khani Maynaq Y; Lin E; Genung N; Hering H; Guckian K; Martarello L; Kaliszczak M; Halldin C
ACS Chem Neurosci; 2023 Jul; 14(14):2560-2568. PubMed ID: 37377046
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.
Li B; Li H; Hu CW; Jiang J
Nat Commun; 2017 Sep; 8(1):666. PubMed ID: 28939839
[TBL] [Abstract][Full Text] [Related]
18. OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area.
Toivonen MH; Pöllänen E; Ahtiainen M; Suominen H; Taaffe DR; Cheng S; Takala T; Kujala UM; Tammi MI; Sipilä S; Kovanen V
Exp Gerontol; 2013 Dec; 48(12):1501-4. PubMed ID: 24365779
[TBL] [Abstract][Full Text] [Related]
19. O-Linked N-Acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Interact with Mi2β Protein at the Aγ-Globin Promoter.
Zhang Z; Costa FC; Tan EP; Bushue N; DiTacchio L; Costello CE; McComb ME; Whelan SA; Peterson KR; Slawson C
J Biol Chem; 2016 Jul; 291(30):15628-40. PubMed ID: 27231347
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of
Declercq L; Rombouts F; Koole M; Fierens K; Mariën J; Langlois X; Andrés JI; Schmidt M; Macdonald G; Moechars D; Vanduffel W; Tousseyn T; Vandenberghe R; Van Laere K; Verbruggen A; Bormans G
J Nucl Med; 2017 Jun; 58(6):975-981. PubMed ID: 28232614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
